Oculus Innovative Sciences Receives Mexican Ministry of Health Approval of Microcyn(R)-Based Hydrogel for Management of Scars

Oculus Innovative Sciences Receives Mexican Ministry of Health Approval of
Microcyn(R)-Based Hydrogel for Management of Scars

Latin American Partner, More Pharma, Targeting Q3 2014 Launch in Mexico

PETALUMA, Calif., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs,
manufactures and markets prescription and non-prescription products 27
countries, today announced a regulatory approval in Mexico for the company's
new Microcyn®-based scar management hydrogel, under the brand name Epicyn™.

Bruce Thornton, executive vice president of Oculus said: "From a corporate
perspective, this is just the first of many opportunities for our new scar
management hydrogel formulation outside the United States.In addition to the
approval by the Mexican Ministry of Health, our Latin American partner, More
Pharma, in parallel with the introduction of the new Epicyn™ Scar Hydrogel in
the Mexican dermatology market, intends to move forward to secure regulatory
approvals, and subsequent product launches, in additional Latin American
countries as well.We are exceedingly proud of our teams in both Mexico and
the United States for working in tandem to secure respective regulatory
approvals."Oculus announced FDA 510(k) regulatory clearance for the Microcyn®
Scar Management HydroGel this past week.

The medical device approval by the Mexican Ministry of Health is for the care
of keloid and hypertrophic scars. In preparation for a commercial launch in
the summer of 2014, More Pharma, in concert with Oculus, plans to conduct an
additional clinical study in the first half of 2014, similar to one conducted
for the FDA in the United States.This clinical study will evaluate the safety
and efficacy profile of Epicyn™ relative to the current standard of scar
management in Mexico, thus providing key opinion leaders the clinical data to
support adoption of the new Microcyn-based technology.

Guillermo Ibarra, More Pharma's CEO said, "Since we acquired the license to
the Microcyn-based products in 2012, our customers have come to recognize the
Microcyn Technology as a highly efficacious product in both advanced wound
care and dermatology.This new scar management hydrogel will simply build upon
this established legacy of safety and success in Mexico.We look forward to
bringing doctors and patients in Mexico, Central America, Caribbean and other
Latin American countries a genuine advance in the management of scars."

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 27
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard ofpatient care and lowering overall healthcare costs.The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found

About More Pharma

Founded in 2007, More Pharma is a pharmaceutical company with strong growth
performance and a team of more than 300 people. The company has a talented
sales and marketing team with significant prior experience with large
international pharmaceutical companies.They have ample funding and support by
their renowned financial sponsors, Southern Cross Group and Evercore, both of
which manage more than $1 billion of venture funds.The company is dedicated
to finding solutions to healthcare challenges via product development,
in-licensing and product acquisitions.With headquarters in Mexico City, More
Pharma has a presence in Mexico, Latin America and the Caribbean.More
information can be found at www.morepharmacorp.com/eng/compania.php

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "growth," "expansion" and"build,"among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2013. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:

         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
Press spacebar to pause and continue. Press esc to stop.